ERBB2 and neoplasm: In this retrospective study, we identified all patients who underwent IHC testing for HER2 status and comprehensively assessed their clinical parameters, BRCA status, IHC biomarker status (mismatch repair [MMR] protein levels and programmed cell death ligand 1 [PD-L1] expression), and tumor NGS profiles.